Internal Medicine, Endocrinology, Diabetes, & Metabolism · South Boston, VA
NPI
1700881885
Since 2005
Specialty
Internal Medicine, Endocrinology, Diabetes, & Metabolism
Code 207RE0101X
Group practices
2
Medicare group memberships
Hospitals
4
Hospital affiliations
2232 Wilborn Ave, Ste B
South Boston, VA, 24592
Phone (434) 575-5844
Groups this clinician bills Medicare through
Medicare paid, 2024
$100K
1,286 services
Medicare patients, 2024
586
Average age 75
Drug cost, 2024
$2.4M
10,338 prescriptions
Company payments, 2025
$420
From 7 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Tessie Otero-Truitt was code 99214 (office e&m - established), 931 times for 452 patients. In total Tessie Otero-Truitt billed 1,286 services in 11 codes, and Medicare paid $100K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2016-01-14.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 931 | 452 | $85.76 | $80K |
| 99232 Hospital E&M - Subsequent | Facility | 88 | 64 | $54.48 | $4,794 |
| 99203 Office E&M - New | Office | 73 | 73 | $79.26 | $5,786 |
| 99233 Hospital E&M - Subsequent | Facility | 42 | 41 | $81.63 | $3,428 |
| 99213 Office E&M - Established | Office | 29 | 28 | $55.14 | $1,599 |
| 99223 Hospital E&M - Initial | Facility | 22 | 21 | $133.92 | $2,946 |
| 99238 Hospital Discharge Management | Facility | 17 | 16 | $59.57 | $1,013 |
By year: 2022 $127K for 1,835 services; 2023 $117K for 1,481 services; 2024 $100K for 1,286 services.
Medicare prescription drug claims, 2024
In 2024, the drug Tessie Otero-Truitt prescribed most often to Medicare patients was Levothyroxine Sodium, with 1,498 prescriptions and refills. In total Tessie Otero-Truitt wrote 10,338 Medicare prescriptions that cost $2.4M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Levothyroxine Sodium Generic | 1,498 | 3,194 | 260 | $8,989 |
| Metformin Hcl Generic | 560 | 1,212 | 134 | $1,671 |
| Lantus Solostar Insulin Glargine,hum.Rec.Anlog | 549 | 878 | 117 | $75K |
| Atorvastatin Calcium Generic | 391 | 902 | 89 | $2,512 |
| Ozempic Semaglutide | 346 | 626 | 75 | $597K |
| Humalog Kwikpen U-100 Insulin Lispro | 331 | 509 | 82 | $92K |
| Tresiba Flextouch U-100 Insulin Degludec | 323 | 557 | 84 | $171K |
| Novolog Flexpen Insulin Aspart | 288 | 464 | 82 | $72K |
| Gabapentin Generic | 264 | 390 | 50 | $2,222 |
| Methimazole Generic | 256 | 476 | 57 | $2,499 |
| Glimepiride Generic | 225 | 432 | 45 | $989 |
| Amlodipine Besylate Generic | 211 | 481 | 53 | $1,151 |
| Nano 2nd Gen Pen Needle Pen Needle, Diabetic | 205 | 301 | 54 | $15K |
| Omnipod Dash Pods (Gen 4) Insulin Pump Cart,cont Inf,bt | 184 | 196 | 22 | $185K |
| Insulin Lispro Kwikpen U-100 Insulin Lispro | 178 | 251 | 46 | $31K |
Brand drugs: 3,887 claims; generic drugs: 5,522 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Tessie Otero-Truitt $420 ($420 in general payments such as food, travel and fees) from 7 companies. The largest payer was Novo Nordisk Inc with $275.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.